The 2026 European Hematology Association (EHA) Congress was held in Stockholm, Sweden from 11 to 14 June 2026.

Conference highlights include:

• TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy
• Gilteritinib versus midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia eligible for intensive therapy: Results from the phase III HOVON156/AMLSG28-18/PASHA trial

This post-meeting report features commentary from our analysts on specific presentations. It also includes a compilation of data events added in conjunction with the meeting.